drugset / Trial / NCT00634062

Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder

NCT00634062

Phase 4 Completed 28 enrolled Mclean Hospital GlaxoSmithKline · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study investigates the hypothesis that instability in mood in patients with borderline personality disorder will respond the mood stabilizing medication lamotrigine.

Timeline

Start
2004-12
Primary completion
2007-09
Completion
2007-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lamotrigine Small molecule 25 mg Oral